Behcet's disease

被引:0
|
作者
Saadoun, D. [1 ,2 ,3 ,4 ]
机构
[1] Hop La Pitie Salpetriere, Dept Med Interne & Immunol Clin, 83,Blvd Hop, F-75013 Paris, France
[2] INSERM, UMR S 959, F-75013 Paris, France
[3] CNRS, FRE3632, F-75005 Paris, France
[4] RHU IMAP, Paris, France
来源
REVUE DE MEDECINE INTERNE | 2023年 / 44卷
关键词
Vasculitis; Behcet's disease; Biotherapiesa; VENOUS THROMBOSIS; MORTALITY;
D O I
10.1016/j.revmed.2023.10.116
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Behcet's disease (BD) is a systemic large-vessel vasculitis characterized by a wide clinical spectrum including recurrent oral and genital ulcerations, uveitis, vascular, neurological, articular, and gastrointestinal manifestations. Therapeutic management of BD depends of the clinical presentation and organ involved. Although colchicine, nonsteroidal antiinflammatory agents and topical treatments with corticosteroidsare often sufficient for mucocutaneous and joint involvement, a more aggressive approach with immunosuppressive agents is warranted for severe manifestations such as posterior uveitis, retinal vasculitis, vascular, neurological and gastrointestinal involvement. However, some patients still have refractory disease, relapses, sight threatening eye disease, or irreversible organ damage. Recent improvements in the understanding of the pathogenic mechanisms have led to the identification of potential targets and future therapies for BD. In contrast to current non-specific immunosuppressive agents, the emergenceof immunomodulatory drugs provides the possibility of interfering with specific pathogenic pathways. Novel targeted immunosuppressive therapies might be used in the future for BD.
引用
收藏
页码:A299 / A301
页数:3
相关论文
共 50 条
  • [31] Behcet's disease
    Delbrel, X
    Fach, J
    Neau, D
    LongyBoursier, M
    REVUE DE MEDECINE INTERNE, 1997, 18 : S342 - S343
  • [32] Behcet's disease
    Kurokawa, MS
    Suzuki, N
    CLINICAL AND EXPERIMENTAL MEDICINE, 2004, 4 (01) : 10 - 20
  • [33] Behcet's disease
    Kurokawa, MS
    Yoshikawa, H
    Suzuki, N
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 25 (05) : 557 - 568
  • [34] eComment. Behcet's disease or Adamantiades-Behcet's disease?
    Dimitrakakis, Georgios
    Dimitrakaki, Inetzi A.
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2012, 14 (03) : 373 - 374
  • [35] How to diagnose Behcet's and intestinal Behcet's disease?
    Celik, A. F.
    Pamuk, Oe. N.
    Melikoglu, M.
    Yazici, H.
    IBD 2007 - ACHIEVEMENTS IN RESEARCH AND CLINICAL PRACTICE, 2008, 159 : 118 - 128
  • [36] Adamantiades-Behcet's disease (Behcet's disease) and COVID-19
    Zouboulis, C. C.
    van Laar, J. A. M.
    Schirmer, M.
    Emmi, G.
    Fortune, F.
    Gul, A.
    Kirino, Y.
    Lee, E. -S.
    Sfikakis, P. P.
    Shahram, F.
    Wallace, G. R.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (09) : E541 - E543
  • [37] Behcet's disease as a systemic disease
    Mat, M. Cem
    Sevim, Aysegul
    Fresko, Izzet
    Tuzun, Yalcin
    CLINICS IN DERMATOLOGY, 2014, 32 (03) : 435 - 442
  • [38] Coeliac disease and Behcet's disease
    Aldersley, MA
    James, TE
    Markham, AF
    Howdle, PD
    BRITISH JOURNAL OF OPHTHALMOLOGY, 1997, 81 (08) : 710 - 710
  • [39] Gastrointestinal disease in Behcet's disease
    Ward, EM
    Woodward, TA
    Mazlumzadeh, M
    Calamia, KT
    ADAMANTIADES-BEHCET'S DISEASE, 2003, 528 : 459 - 464
  • [40] Behcet's disease.
    Cheng, TO
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08): : 588 - 588